Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 177
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C89EC034F74EN
Leaflet:

Download PDF Leaflet

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2016, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 7, 2, 17, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 7, 5 and 4 molecules, respectively.Cytomegalovirus (HHV-5) Infections.

Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cytomegalovirus (HHV-5) Infections Overview
Therapeutics Development
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
Adicet Bio, Inc.
AIMM Therapeutics BV
Astellas Pharma Inc
Atara Biotherapeutics Inc
AvidBiotics Corp
Biotest AG
Chimerix Inc
China Biologic Products Inc
CyTuVax BV
Fate Therapeutics Inc
GlaxoSmithKline Plc
Hookipa Biotech AG
Kadmon Corp LLC
Laboratoires Thea SA
Merck & Co Inc
Microbiotix Inc
Mymetics Corp
Novartis AG
Pfizer Inc
Phoenix Biotechnology Inc
Savoy Pharmaceuticals, Inc.
Sigma-Tau SpA
Themis Bioscience GmbH
Trellis Bioscience Inc
Vakzine Projekt Management GmbH
VBI Vaccines Inc
Vical Inc
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AIC-387 - Drug Profile
AIC-476 - Drug Profile
AIC-813 - Drug Profile
AL-18 - Drug Profile
Antibody for Human Cytomegalovirus Infection - Drug Profile
ASP-0113 - Drug Profile
brincidofovir - Drug Profile
BT-084 - Drug Profile
Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile
Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile
Cellular Immunotherapy for Infectious Disease - Drug Profile
Cellular Immunotherapy for Infectious Diseases - Drug Profile
Cellular Immunotherapy for Viral Infections - Drug Profile
Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile
Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
CMX-669 - Drug Profile
CSJ-148 - Drug Profile
CyMVectin - Drug Profile
cytomegalovirus (virus like particle) vaccine - Drug Profile
Cytomegalovirus (virus like particle) vaccine - Drug Profile
Cytomegalovirus vaccine - Drug Profile
Cytomegalovirus vaccine - Drug Profile
Cytomegalovirus vaccine - Drug Profile
filociclovir - Drug Profile
ganciclovir - Drug Profile
Gene Therapy for Cytomegalovirus Infections - Drug Profile
HB-101 - Drug Profile
letermovir - Drug Profile
maribavir - Drug Profile
MBX-2168 - Drug Profile
Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile
Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile
Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile
Pentamer - Drug Profile
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile
PepVax - Drug Profile
ProTmune - Drug Profile
PTX-3 - Drug Profile
RBT-301 - Drug Profile
Recombinant Peptide for Infectious Diseases - Drug Profile
Recombinant Protein for CMV - Drug Profile
RKP-00156 - Drug Profile
Small Molecule for Cytomegalovirus - Drug Profile
Small Molecules for CMV Infections - Drug Profile
Small Molecules for CMV infections and Cancer - Drug Profile
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile
Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile
Triplex - Drug Profile
TRL-345 - Drug Profile
V-160 - Drug Profile
VBI-1501A - Drug Profile
Viralym-C - Drug Profile
Viroprev - Drug Profile
VPM-2001 - Drug Profile
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 173

LIST OF TABLES

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Mymetics Corp, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H2 2016
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H2 2016
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H2 2016
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H2 2016
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H2 2016
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H2 2016
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H2 2016 161

LIST OF FIGURES

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H2 2016
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: